WO2012019188A3 - Methods and compositions for the inhibition of fructokinase - Google Patents

Methods and compositions for the inhibition of fructokinase Download PDF

Info

Publication number
WO2012019188A3
WO2012019188A3 PCT/US2011/046938 US2011046938W WO2012019188A3 WO 2012019188 A3 WO2012019188 A3 WO 2012019188A3 US 2011046938 W US2011046938 W US 2011046938W WO 2012019188 A3 WO2012019188 A3 WO 2012019188A3
Authority
WO
WIPO (PCT)
Prior art keywords
fructokinase
inhibition
compositions
methods
ketohexokinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/046938
Other languages
French (fr)
Other versions
WO2012019188A2 (en
Inventor
Richard J. Johnson
Miguel A. Lanaspa
Takuji Ishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Priority to EP11815418.6A priority Critical patent/EP2600897A2/en
Priority to JP2013523385A priority patent/JP2013533289A/en
Priority to US13/814,568 priority patent/US9387245B2/en
Publication of WO2012019188A2 publication Critical patent/WO2012019188A2/en
Publication of WO2012019188A3 publication Critical patent/WO2012019188A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease.
PCT/US2011/046938 2010-08-06 2011-08-08 Methods and compositions for the inhibition of fructokinase Ceased WO2012019188A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP11815418.6A EP2600897A2 (en) 2010-08-06 2011-08-08 Methods and compositions for the inhibition of fructokinase
JP2013523385A JP2013533289A (en) 2010-08-06 2011-08-08 Methods and compositions for inhibiting fructokinase
US13/814,568 US9387245B2 (en) 2010-08-06 2011-08-08 Methods and compositions for the inhibition of fructokinase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37125510P 2010-08-06 2010-08-06
US61/371,255 2010-08-06

Publications (2)

Publication Number Publication Date
WO2012019188A2 WO2012019188A2 (en) 2012-02-09
WO2012019188A3 true WO2012019188A3 (en) 2012-06-14

Family

ID=45560112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046938 Ceased WO2012019188A2 (en) 2010-08-06 2011-08-08 Methods and compositions for the inhibition of fructokinase

Country Status (4)

Country Link
US (1) US9387245B2 (en)
EP (1) EP2600897A2 (en)
JP (1) JP2013533289A (en)
WO (1) WO2012019188A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015217301A1 (en) * 2014-02-11 2016-08-25 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA compositions and methods of use thereof
SI3397631T1 (en) * 2015-12-29 2022-01-31 Pfizer Inc. Substituted 3-azabicyclo(3.1.0)hexanes as ketohexokinase inhibitors
WO2017180743A1 (en) * 2016-04-12 2017-10-19 Regents Of The University Of Colorado, A Body Corporate Targeting amp deaminase 2 for ameliorating craving for sugar and other substances
EA035363B1 (en) * 2016-11-17 2020-06-02 Пфайзер Инк. Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
EP4011396A1 (en) 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Releasable conjugates
US12161621B2 (en) * 2018-07-16 2024-12-10 The Regents Of The University Of Colorado Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease
AU2019340472A1 (en) 2018-09-12 2021-04-01 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
CA3105385A1 (en) * 2018-09-18 2020-03-26 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
BR112022017822A2 (en) * 2020-03-06 2022-11-08 Alnylam Pharmaceuticals Inc KETEXOCINASE (KHK) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202302847A (en) 2021-02-26 2023-01-16 美商艾拉倫製藥股份有限公司 Ketohexokinase (khk) irna compositions and methods of use thereof
WO2025128632A1 (en) * 2023-12-12 2025-06-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating ketohexokinase (khk)-associated diseases
CN118703500B (en) * 2024-01-30 2025-06-17 大连医科大学 A combination of small interfering RNA and short hairpin RNA sequences of fructokinase KHK and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007413A1 (en) * 1999-07-22 2001-02-01 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
JP2007284387A (en) * 2006-04-18 2007-11-01 Kumiai Chem Ind Co Ltd 3-Pyrazolylphenyl sulfide derivative and insecticide, acaricide, nematicide containing it as an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024902A2 (en) * 2006-08-23 2008-02-28 University Of Florida Research Foundation, Inc. Targeting of fructokinase as therapy for cardiovascular disease, metabolic syndrome, and renal disease
WO2011088272A2 (en) * 2010-01-13 2011-07-21 The Regents Of The University Of Colorado Selective ampd2 inhibitors and methods for using the same
JP2013525370A (en) * 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． Indazole compounds useful as keto hexokinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007413A1 (en) * 1999-07-22 2001-02-01 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
JP2007284387A (en) * 2006-04-18 2007-11-01 Kumiai Chem Ind Co Ltd 3-Pyrazolylphenyl sulfide derivative and insecticide, acaricide, nematicide containing it as an active ingredient

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARUNA ASIPU ET AL.: "Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria", DIABETES, vol. 52, no. 9, 2003, pages 2426 - 2432 *
CHRISTINE P. DIGGLE ET AL.: "Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme", JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, vol. 57, no. 8, 2009, pages 763 - 774 *
PIETRO CIRILLO ET AL.: "Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells", J. AM. SOC. NEPHROL., vol. 20, no. 3, 2009, pages 545 - 553, XP055187675, DOI: doi:10.1681/ASN.2008060576 *

Also Published As

Publication number Publication date
JP2013533289A (en) 2013-08-22
US20130224218A1 (en) 2013-08-29
US9387245B2 (en) 2016-07-12
WO2012019188A2 (en) 2012-02-09
EP2600897A2 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
Morris et al. The role of angiotensin II in nonalcoholic steatohepatitis
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
CY1112320T1 (en) TAPENDADOL TITLE
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2009129464A3 (en) Method for treating acute pain with a formulated drug depot in combination with a liquid formulation
WO2010045415A3 (en) Topical nsaid compositions having sensate component
WO2012062925A3 (en) Compounds and methods for treating pain
EA201300121A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PREPARATION
WO2007073486A3 (en) Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2012055967A3 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
IL215579A (en) Use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition for treating diseases based on the expression of mcp-1, cx3cr1 and p40
EP2262778B8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
HU0800434D0 (en) Template to determine the places of the injections, especially for regular medicament injection and/or blood testing
HK1198869A1 (en) Combination treatments for hepatitis c
WO2010136508A3 (en) Stem cell targeting
WO2011150022A3 (en) Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
MX2009011900A (en) Diabetic wound healing.
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2009004995A1 (en) Method of fixing and expressing physiologically active substance
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
FR2928149B1 (en) AZETIDINE-DERIVED COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815418

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013523385

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011815418

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13814568

Country of ref document: US